Summit Global Investments Has $9.66 Million Stake in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Summit Global Investments lifted its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 75.5% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 729,200 shares of the company’s stock after purchasing an additional 313,642 shares during the period. Summit Global Investments’ holdings in Takeda Pharmaceutical were worth $9,655,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Versant Capital Management Inc acquired a new position in shares of Takeda Pharmaceutical during the fourth quarter worth approximately $26,000. Wilmington Savings Fund Society FSB acquired a new position in shares of Takeda Pharmaceutical during the third quarter worth approximately $40,000. BNP Paribas Financial Markets lifted its position in shares of Takeda Pharmaceutical by 416.0% during the third quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after purchasing an additional 2,596 shares in the last quarter. Smithfield Trust Co lifted its position in shares of Takeda Pharmaceutical by 76.9% during the third quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after purchasing an additional 1,490 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock worth $47,000 after purchasing an additional 1,976 shares in the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Up 0.2 %

Shares of NYSE TAK opened at $15.20 on Friday. The company’s 50 day simple moving average is $13.96 and its 200 day simple moving average is $13.92. Takeda Pharmaceutical Company Limited has a fifty-two week low of $12.58 and a fifty-two week high of $15.31. The firm has a market capitalization of $48.35 billion, a P/E ratio of 37.99, a P/E/G ratio of 0.24 and a beta of 0.46. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings data on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. On average, analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.